About 3,153 results

ALLMedicine™ Hidradenitis Suppurativa Center

Research & Reviews  1,108 results

The Use of Biologics During the COVID-19 Pandemic.
Dermatologic Clinics; Jones ME, Kohn AH et. al.

Sep 25th, 2021 - During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This ...

Single-center survey of biologic use for inflammatory skin diseases during the coronavi...
The Journal of Dermatology; Kado S, Kamiya K et. al.

Sep 23rd, 2021 - Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The ongoing COVID-19 pandemic has affected both daily life and medical care; therefore, the aim of this study was to analyze the use of ...

Improvement in Quality of Life and Pain in Patients With Hidradenitis Suppurativa After...
Dermatologic Surgery : Official Publication for American ... Dick J, Kröhl V et. al.

Sep 20th, 2021 - Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that affects patients' quality of life (QoL). To investigate changes in QoL in patients with HS after wide local excision (WLE) and to examine the level of pain, rate of postoper...

Biologic therapy is not associated with increased COVID-19 severity in Hidradenitis Sup...
Journal of the American Academy of Dermatology; Naik HB, Alhusayen R et. al.

Sep 20th, 2021 - Biologic therapy is not associated with increased COVID-19 severity in Hidradenitis Suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry.|2021|Naik HB,Alhusayen R,Frew J,Guilbault S,Hills NK,|

LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clinda...
Dermatology (Basel, Switzerland); Schultheis M, Staubach P et. al.

Sep 19th, 2021 - Hidradenitis suppurativa (HS) is a chronic, inflammatory, burdensome skin disease where medical first-line treatment is still limited to long-term, topical and/or systemic antibiotics. The RELIEVE study aimed at evaluating the efficacy of LAight® ...

see more →

Guidelines  1 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

see more →

Drugs  1 results see all →

News  150 results

Two Studies Add to Knowledge Base of Biosimilar Use in Psoriasis, HS

Apr 29th, 2021 - A cohort study of psoriasis patients in Denmark found that a nonmedical switch from brand name adalimumab to adalimumab biosimilars was not associated with drug retention at 1 year. And another study, a small, single-center retrospective study of ...

New Analysis Eyes the Surgical Landscape for Hidradenitis Suppurativa

Mar 24th, 2021 - Among patients who undergo surgery for hidradenitis suppurativa (HS), wide excision and flap-based reconstruction are associated with lower postsurgical recurrence, yet these options should be balanced against potentially higher morbidity of exten...

Inflammatory Skin Diseases and CKD Risk: What’s the Link?

Mar 23rd, 2021 - Takeaway Atopic eczema, psoriasis and hidradenitis suppurativa were weakly associated with chronic kidney disease (CKD), independent of obesity, cardiovascular morbidity or non-biologic nephrotoxic skin medications. No evidence supporting this ass...

Managing Hyperhidrosis: Ask Questions First

Mar 15th, 2021 - A wide variety of medications exists for treating hyperhidrosis, a dermatologist told colleagues, but before prescribing anything to a pediatric patient, he recommended, ask the patient a simple question: "What bothers you the most?" The answer wi...

Adalimumab Enhances Primary Wound Closure After HS Surgery

Feb 3rd, 2021 - Delaying surgical reconstruction of fistula structures until after patients with hidradenitis suppurativa (HS) have been on adalimumab for a minimum of 6 months transforms primary wound closure into a highly attractive option, a pilot study sugges...

see more →

Patient Education  1 results see all →